Lee Sung 4

What Happened

• Sung Lee, Chief Financial Officer of Cytokinetics (CYTK), exercised 1,112 stock options and immediately sold those 1,112 shares in an open-market transaction on July 1, 2026.
• Exercise cost: 1,112 shares × $48.51 = $53,943. Open-market sale proceeds: 1,112 shares × $87.79 = $97,622. Net proceeds before taxes/fees were roughly $43,679.
• This sequence (exercise then immediate sale) is a cashless/same-day sale of exercised options rather than a straightforward buy-as-investment.

Key Details

• Transaction date: July 1, 2026. Filed: July 2, 2026 (appears timely).
• Exercise (code M): acquired 1,112 shares at $48.51 (total $53,943).
• Open-market sale (code S): sold 1,112 shares at $87.79 (total $97,622).
• Filing also shows a separate derivative-disposition line for 1,112 shares at $0.00; this line typically records the conversion/settlement aspect of the exercised options—see the filing footnotes for the issuer’s accounting details.
• Shares owned after the transaction: not specified in the provided excerpt of the filing.

Context

• Because the exercised shares were immediately sold, this is primarily a liquidity transaction (cashing out option gains) rather than an additional personal purchase of stock—such transactions are common for option holders and do not necessarily signal a change in the insider’s view of the company.
• For full details (including any tax withholding, plan instructions, or footnotes explaining the $0 derivative line), review the complete Form 4 filing (Accession: 0001061983-26-000072).